Becker's Healthcare July 18, 2024
Drugmakers Pfizer and Valneva are one step closer to obtaining FDA approval for what would be the first Lyme disease vaccine after publishing positive results from a phase 3 trial, the companies announced July 17.
Lyme disease, caused by tick bites, has been a nationally notifiable condition since 1991, according to the CDC, and it is estimated that each year around 476,000 individuals are diagnosed with the disease.
The vaccine in development would be given as a series of three doses, followed by an extra booster shot one year after the initial vaccination series. The phase 3 study will monitor participants until 2025, but so far, has revealed positive results.
“The completion of the primary series of our VALOR...
Today's Sponsors
Today's Sponsor